Loading...
Cipla Limited — Budesonide Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #1 for Budesonide · $53.0M export value · DGFT Verified
Cipla Limited is the #1 Indian exporter of Budesonide with $53.0M in export value and 1,060 verified shipments. Cipla Limited holds a 27.8% market share in Budesonide exports across 31 countries. The company exports 98 pharmaceutical products worth $1.1B across 26 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $19.0M | 412 | 46.9% |
| ALGERIA | $5.6M | 117 | 13.7% |
| UNITED ARAB EMIRATES | $3.5M | 75 | 8.6% |
| SAUDI ARABIA | $2.7M | 65 | 6.8% |
| SRI LANKA | $2.2M | 65 | 5.4% |
| CHILE | $1.3M | 79 | 3.2% |
| GERMANY | $1.2M | 29 | 3.0% |
| OMAN | $796.5K | 26 | 2.0% |
| YEMEN | $487.7K | 12 | 1.2% |
| MOROCCO | $450.0K | 9 | 1.1% |
Cipla Limited exports Budesonide to 34 countries. The largest destination is UNITED STATES accounting for 46.9% of Cipla Limited's Budesonide shipments, followed by ALGERIA (13.7%) and UNITED ARAB EMIRATES (8.6%). These destinations reflect Cipla Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CIPLA USA INC UPS SUPPLY CHAIN SOLU | UNITED STATES | $15.9M | 331 |
| BIOPHARM DISTRIBUTION SPA | ALGERIA | $3.0M | 60 |
| ACINO PHARMACEUTICALS FZ LLC | UNITED ARAB EMIRATES | $2.2M | 47 |
| BIOPHARM DISTRIBUTION SPA, | ALGERIA | $1.7M | 38 |
| BREATHEFREE LANKA PVT LTD |
India exported $70.6M worth of Budesonide through 9,145 shipments from 275 suppliers to 115 countries, serving 609 buyers globally. Cipla Limited contributes $53.0M to this total, accounting for 27.8% of India's Budesonide exports. Cipla Limited ships Budesonide to 34 countries through 101 buyers.
Cipla Limited's average Budesonide shipment value is $50.0K per consignment, based on 1,060 shipments totaling $53.0M. The largest destination is UNITED STATES (46.9% of Cipla Limited's Budesonide exports).
Cipla Limited ranks #1 among 275 Indian Budesonide exporters with a 27.8% market share. The top 3 exporters are CIPLA LIMITED ($53.0M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($7.8M), ZYDUS LIFESCIENCES LIMITED ($2.4M). Cipla Limited processed 1,060 shipments to 31 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| BUDESONIDE INHALATION SUSPENSION 0.5MG/2 | $4.5M | 91 |
| BUDESONIDE INHALATION SUSPENSION 1MG/2ML | $1.6M | 32 |
| BUDECORT 200 INHALER WITH DOSE IDICATOR (BUDESONIDE 200MCG) 1 X 200 MD | $1.0M | 21 |
| BUDESONIDE INHALATION SUSPENSION 0.25MG/ | $900.0K | 18 |
| BUDECORT 0.5 MG RESPULES (BUDESONIDE 0.5 | $700.3K | 15 |
| BUDESONIDE INHALATION SUSPENSION 0.5MG/2ML; NDC NO. 69097-319-87; ANDA NO. 205710 PACK SIZE 6 X 5 X 2 ML | $650.0K | 13 |
| BUDECORT 200 INHALER WITH DOSE IDICATOR BUDESONIDE 200 MCG | $565.6K | 12 |
| BUDECORT 200 INHALER WITH DOSE IDICATOR(BUDESONIDE 200 MCG).NOS | $541.1K | 12 |
What Cipla Limited must comply with to export Budesonide to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | CIPLA LIMITED ★ | $53.0M | 1,060 | 31 | $50.0K |
| 2 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $7.8M | 166 | 3 | $47.1K |
| 3 | ZYDUS LIFESCIENCES LIMITED | $2.4M | 78 | 7 | $30.9K |
Cipla Limited ranks #1 among 275 Indian Budesonide exporters. Average shipment value of $50.0K compared to the market average of $256.7K. The closest competitors by value are SUN PHARMACEUTICAL INDUSTRIES LIMITED and ZYDUS LIFESCIENCES LIMITED.
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 1,990 | 21.8% |
| DELHI AIR CARGO ACC (INDEL4) | 1,616 | 17.7% |
| DELHI AIR | 1,404 | 15.4% |
| SAHAR AIR CARGO ACC (INBOM4) | 1,213 | 13.3% |
| Delhi Air | 419 | 4.6% |
| Bombay Air | 386 | 4.2% |
| NHAVA SHEVA SEA (INNSA1) | 303 | 3.3% |
| Delhi Air Cargo | 152 | 1.7% |
Cipla Limited also exports these respiratory products. Each links to the detailed product page.
Visual overview of India's budesonide supplier profile for Cipla Limited — top suppliers, destinations, pricing, and trade routes
Cipla's export operations are currently navigating a complex geopolitical landscape. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These challenges are particularly acute for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management.
In the United States, recent import policies, including the imposition of 100% tariffs on branded or patented pharmaceutical products effective October 2025, have introduced additional hurdles for Indian exporters. While generic drugs, a significant component of Cipla's portfolio, may be less affected, the overall trade environment demands vigilance and adaptability. Conversely, the India-European Union Free Trade Agreement, concluded in January 2026, offers a promising avenue for Cipla. The agreement aims to eliminate tariffs on pharmaceuticals, potentially enhancing Cipla's competitiveness in the European market and offsetting challenges faced in other regions.
Maintaining stringent quality standards is paramount for Cipla, given the diverse regulatory environments across its export markets. The company has demonstrated a strong commitment to compliance, as evidenced by the U.S. Food and Drug Administration's (FDA) classification of its Bengaluru facility as Voluntary Action Indicated (VAI) in October 2025. This classification is crucial for sustaining and expanding Cipla's presence in the U.S. market. Additionally, the European Union's evolving regulatory framework, including the Falsified Medicines Directive, necessitates continuous adaptation to ensure compliance and maintain market access.
Cipla Limited exports 98 products worth $1.1B. Beyond Budesonide, top products include Fluticasone, Amlodipine, Salbutamol, Telmisartan, Salmeterol. View the complete Cipla Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Budesonide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Cipla Limited's Budesonide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Cipla Limited
Full Company Profile →
98 products · $1.1B total trade · 26 categories
| SRI LANKA |
| $1.5M |
| 44 |
| CIPLA USA INC UPS SUPPLY CHAIN SOL | UNITED STATES | $1.3M | 26 |
| ESPARMA PHARMA SERVICES GMBH | GERMANY | $1.0M | 22 |
| TO THE ORDER OF CITIBANK N A ALGERI | ALGERIA | $815.6K | 17 |
| EXELAN PHARMACEUTICALS, INC | UNITED STATES | $699.1K | 19 |
| BREATHEFREE LANKA PRIVATE LIMITED | SRI LANKA | $651.4K | 21 |
Cipla Limited supplies Budesonide to 101 buyers globally. The largest buyer is CIPLA USA INC UPS SUPPLY CHAIN SOLU (UNITED STATES), followed by BIOPHARM DISTRIBUTION SPA (ALGERIA) and ACINO PHARMACEUTICALS FZ LLC (UNITED ARAB EMIRATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| BUDECORT 200 INHALER WITH DOSE INDICATOR(BUDESONIDE 200 MCG)NOS |
| $540.2K |
| 12 |
| BUDESONIDE INHALATION SUSPENSION 0.5MG/2ML; NDC NO. 69097-319-87; ANDA NO. 205710 PACK SIZE 6X5X2 MLNOS | $497.5K | 12 |
Cipla Limited exports 480 distinct Budesonide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is BUDESONIDE INHALATION SUSPENSION 0.5MG/2 with 91 shipments worth $4.5M.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 115+ countries, 609+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Cipla Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Budesonide. For current shipment-level data, contact TransData Nexus.